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Abstract34 
Tablet disintegration characterisation is used in pharmaceutical research, development, and quality 35 
control.  Standard methods used to characterise tablet disintegration are often dependent on visual 36 
observation in measurement of disintegration times. This presents a challenge for disintegration 37 
studies of tablets in opaque, physiologically relevant media that could be useful for tablet 38 
formulation optimisation. In this study is explored an application of texture analysis disintegration 39 
testing, a non-visual, quantitative means of determining tablet disintegration end point, by analysing 40 
the disintegration behaviour of two tablet formulations in opaque media. In this study, the 41 
disintegration behaviour of one tablet formulation manufactured in-house, and Sybedia Flashtab 42 
placebo tablets in water, bovine, and human milk were characterised. A novel method is presented 43 
to characterise the disintegration process and to quantify the disintegration end points of the tablets 44 
in various media using load data generated by a texture analyser probe. The disintegration times in 45 
the different media were found to be statistically different (P<0.0001) from one another for both 46 
tablet formulations using one-way ANOVA. Using the Tukey post-hoc test, the Flashtab placebo 47 
tablets were found not to have statistically significant disintegration times from each other in human 48 
versus bovine milk (adjusted P value 0.1685). 49 
Key words 50 
Rapidly disintegrating tablet, texture analysis, infant drug delivery, breast milk, Nipple Shield 51 
Delivery System, NSDS 52 
Acronyms 53 
Active Pharmaceutical Ingredient (API), Nipple Shield Delivery System (NSDS), United States 54 
Pharmacopeia (USP) 55 
1. Introduction 56 
Tablet disintegration properties are characterised during pharmaceutical development to 57 
ensure formulation quality following manufacture.  Tablet disintegration is also important to 58 
characterise because it is a precursor to dissolution (Anwar et al., 2005). Therefore there is a 59 
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continuing need to characterise tablet disintegration behaviour in vitro to ensure that safe and 60 
reliable dosage forms of active pharmaceutical ingredients (APIs) are produced (Donauer and 61 
Lobenberg, 2007).  62 
Conventional tablet disintegration is characterised using methods harmonised across the 63 
U.S. Pharmacopeia (USP), the European Pharmacopoeia, and the Japanese Pharmacopeia. As 64 
described by the USP, to perform the disintegration test, tablets are placed in the USP Apparatus A 65 
within a basket-rack assembly, churned in water, and visually examined to determine disintegration 66 
completion (U.S. Pharmacopeial Convention, 2014a). In this method tablet disintegration is defined 67 
as complete when the tablet appears to have no palpable firm core (U.S. Pharmacopeial Convention, 68 
2014a). The standard method of visual discernment to assess tablet disintegration time could be 69 
complemented with additional quantitative measurement techniques, to aid understanding of tablet 70 
disintegration behaviour. This is especially true for fast release formulations, such as rapidly 71 
disintegrating tablets, whose high speed of disintegration make visual assessment of disintegration 72 
using the USP apparatus challenging. Currently there is no designated method of disintegration 73 
characterisation specifically for rapidly disintegrating tablets in any of the three mentioned 74 
pharmacopoeias (U.S. Pharmacopeial Convention, 2014a).  75 
Experimental quantitative methods for the characterisation of tablet disintegration time has 76 
been developed using a texture analyser (Dor and Fix, 2000)(el-Arini and Clas, 2002)(Szakonyi and 77 
Zelkó, 2013). Disintegration testing via texture analysis could be broadly beneficial for disintegration 78 
testing in opaque media since the technique does not require visually assessing completion of tablet 79 
disintegration. Developing quantitative methods for disintegration testing of tablets in opaque 80 
media, such as milk and other mixtures present in the digestive system, could further support 81 
existing tablet disintegration characterisation methods. This data could be useful for optimising 82 
tablet formulations, like those designed to disintegrate in milks, juices, or other opaque media prior 83 
to administration. In the described study, texture analysis is used for a novel application, specifically 84 
as a method to quantify disintegration time in opaque media. The specific application of developing 85 
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rapidly disintegrating and dispersible tablets to be used in a novel breast milk mediated drug 86 
delivery system for infants is used as an example for the usefulness of this technique.  87 
During texture analysis disintegration testing, a probe is lowered against a disintegrating 88 
tablet in a liquid. In one method, the probe applies a constant load to the tablet and moves at a 89 
variable velocity.  In another method, the probe moves at a constant velocity while applying a 90 
variable load to the tablet.  In the constant load technique, the distance travelled by the probe as 91 
the tablet disintegrates is recorded (Abdelbary et al., 2005). In the constant velocity technique, a 92 
load-displacement curve is generated, from which the in vivo disintegration times have been 93 
predicted from an empirical equation (Szakonyi and Zelkó, 2013). Both methods have shown positive 94 
correlation with in vivo data (Abdelbary et al., 2005) (Dor and Fix, 2000) (Szakonyi and Zelkó, 2013). 95 
In this study, the constant load technique is used to characterize tablet disintegration in opaque 96 
media. 97 
Rapidly disintegrating tablets, also known as fast disintegrating or orally disintegrating 98 
tablets, have formulations designed to disintegrate entirely in the mouth prior to swallowing. These 99 
tablets are defined by their administration method rather than by a disintegration time specification 100 
(U.S. Department of Health and Human Services, 2008). Additionally, dispersible tablets, which are 101 
administered after dispersion in liquids such as water or milk, also have very fast disintegration 102 
times, typically less than 3 min (UNICEF, 2013). There is therefore high patient compliance 103 
associated with the administration of rapidly disintegrating and dispersible tablets to children, 104 
elderly, and those with dysphagia because they reduce administration complications for populations 105 
with difficulty swallowing (Fu et al., 2004).   106 
An administration method for delivering rapidly disintegrating and dispersible tablets 107 
specifically to infants has been proposed using a novel Nipple Shield Delivery System (NSDS) 108 
(Gerrard, Larson, et al., 2013) (Gerrard, Orlu-Gul, et al., 2013) (Hart et al., 2014) (Sokal et al., 2013). 109 
When worn by a mother during breastfeeding, an insert, such as a tablet, is held within the NSDS 110 
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and releases an API into breast milk consumed by the infant (Gerrard, Orlu-Gul, et al., 2013) (see 111 
Figure 1).  112 
The NSDS could potentially provide a simple method for infant drug delivery and a hygienic 113 
and natural means of administering medications to infants.  To understand the dosing and drug 114 
delivery of potential tablet formulations using the device, their disintegration behaviour in human 115 
milk needs to be characterised.  A critical design specification for tablets used in the NSDS is that the 116 
entirety of the API is released into the breast milk within one breastfeed; therefore, disintegration 117 
characterisation of the tablets is especially important. 118 
Characterisation of tablet disintegration in human milk via texture analysis provides a novel 119 
method of screening potential tablet formulations for the NSDS. In addition, disintegration testing in 120 
bovine milk serving as a fed-state gastric fluid model (Anwar et al., 2005) could prove widely 121 
applicable in pharmaceutical development.  122 
2. Materials and methods 123 
Characterisation of tablet disintegration was performed through analysis of position and 124 
load data of a texture analyser probe applying constant load to tablets disintegrating in various 125 
media.  126 
2.1 Media 127 
Disintegration was characterised in a variety of media including deionised water, human 128 
milk, and bovine milk. The three media used in the study were chosen due to their relevance in 129 
previous disintegration characterisation literature and their applications in facilitating tablet 130 
disintegration in numerous applications.  131 
Water was selected because it is the media used in USP disintegration characterisation, and 132 
has been used in the literature for texture analysis disintegration testing previously (Abdelbary et al., 133 
2005)(Dor and Fix, 2000). It is frequently used to dissolve and disintegrate tablets in a variety of 134 
applications including drug delivery, by facilitating reconstitution of dispersible tablets prior to 135 
administration.  136 
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Human milk was selected because thorough understanding of tablet disintegration 137 
behaviour in this fluid is critical to formulation development of tablets to be used in the NSDS.  Other 138 
methods of characterising tablet disintegration behaviour in human milk is challenging since human 139 
milk is not transparent, obstructing visual observation. Therefore, to determine if texture analysis 140 
could be applied to screening tablets for development of dosage formulations appropriate for the 141 
NSDS, human milk was tested as one of the media.   142 
The human milk was obtained from 10 healthy donors (screened negative for HIV 1 and 2, 143 
HTLV I and II, Hepatitis B and C, and Syphilis) who had consented for their milk to be used for 144 
research.  The Cambridge Human Biology Research Ethics Committee at the University of Cambridge 145 
provided ethical approval for all human milk sample use. All of the milk was centrifuged (Sigma-146 
Zentrifugen, Osterode, Germany) for 15 min at 5500 RPM, from which the fat later was removed and 147 
into which the protein layer was resuspended to produce fat-free milk. Milk batches of various fat 148 
compositions were produced through mixing various proportions of fat and fat-free milk, from which 149 
one composition was selected for use in this study (3.4 wt% fat, 1.8 wt% protein, Queen Charlotte’s 150 
and Chelsea Hospital Milk Bank).  Protein content was measured using a standard Bradford Agent 151 
(Sigma Aldrich, Dorset, UK) assay (Bradford, 1976). 152 
Human milk fat content is highly variable, with average fat content varying between 153 
colostrum, transitional, and mature milk. The averages range from 2.6 w/v% to 4.1 w/v% depending 154 
on the time of day, the number of days post-partum, the time within the feed, and the mother 155 
(Emmett and Rogers, 1997). The composition of human milk for the study was chosen such that the 156 
fat content fell within this physiologically relevant range. Prior to the experiments, the human milk 157 
was thawed from -80 ˚C storage in a 3 ˚C refrigerator for 2 days.  158 
The human milk fat content was calculated based on creamatocrit measurements performed 159 
on 1 mL milk samples centrifuged (Sigma-Zentrifugen) for 15 min in 4.6 mm inner diameter, 80 mm 160 
length tubes at 930g.  Creamatocrit values were used in Wang et al.’s creamatocrit to fat correlation 161 
for thawed samples stored at -20 ˚C (Wang et al., 1999). The milk was thawed from -80 ˚C and this 162 
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correlation is assumed to adequately assess fat content for these conditions (Gerrard, Orlu-Gul, et 163 
al., 2013).   164 
Bovine milk, a fluid which has been used to simulate fed-state stomachs in the literature 165 
(Jantratid et al., 2008), was selected because fluid conditions in the stomach are important to 166 
consider for characterisation of tablet medications which are swallowed whole and intended to 167 
disintegrate in the stomach.  Like human milk, bovine milk, being opaque, is also challenging when 168 
used in disintegration characterisation methods which rely on visual observation. Therefore texture 169 
analysis testing, by providing an analytical method of determining disintegration end points, is 170 
advantageous for this fluid.  171 
The bovine milk used in the study was pasteurised, homogenised, bovine milk (Whole Cow 172 
Milk, 4 w/v% fat, 3.3 w/v% protein, J.S. Sainsbury’s, Cambridge, UK), which was thawed from -80 ˚C 173 
storage in a 3 ˚C refrigerator for 2 days prior to use.  174 
2.2 Tablet formulation 175 
Commercial grade as well as tablets manufactured in-house were characterised. Sybedia 176 
Flashtab placebo biconcave tablets with a proprietary composition were supplied by Ethypharm (Le 177 
Grand Quevilly Cedex, France). Biconcave directly compressed tablets containing Sulforhodamine B, 178 
hereafter referred to as SRB tablets, were formulated in-house using the components listed in Table 179 
1. The SRB tablet excipients were chosen based on pre-existing formulations for rapidly 180 
disintegrating tablets (Charoo et al., 2012). These tablets serve as model tablets for NSDS 181 
development. 182 
The SRB tablets were formulated by initially blending the filler, model compound, and 183 
superdisintegrants, followed by blending in the lubricant, sieving at 500 μm, and blending a final 184 
time. The powder blend was directly compressed using a Manesty F3 tablet press (Manesty, 185 
Liverpool, UK) with a biconvex 80 single punch and die set (Holland, Nottingham, UK).   186 
2.3 USP characterisation of tablets 187 
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All tablets were physically characterised using USP methods, aside from the modification 188 
that disintegration testing was performed individually on each tablet rather than in a set of six. This 189 
modification to the USP method allowed more accurate discernment of the standard deviation of 190 
the average disintegration time since the tablets disintegrate so rapidly.  This disintegration testing 191 
was performed using a disintegration apparatus with a basket rack assembly (Copley, Nottingham, 192 
UK). Tablet length, width, and height were measured using calipers. Crushing force was tested using 193 
an Erweka TBH200 hardness tester (Heusenstamm, Germany) with the tablets oriented 194 
diametrically. Physical characterisation data are shown in Table 2. 195 
2.4 Texture analysis characterisation method 196 
Texture analysis disintegration characterisation was performed using a TA.XTplus Texture 197 
Analyser (Stable Microsystems Ltd., UK) equipped with a 14.23 mm diameter probe set to maintain a 198 
constant load of 50g. The load value chosen was found to sufficiently hold the tablets in place during 199 
each experiment, and has been used in other texture analysis studies (Abdelbary et al., 2005). 200 
Exponent Software (Stable Microsystems Ltd., UK) was used to monitor the probe lowering distance 201 
and applied load over time as each tablet disintegrated.   202 
During each test, a tablet was attached vertically to the probe using double-stick tape 203 
(Sellotape, Winsford, UK).  This tablet orientation served to increase the surface area of tablet 204 
exposed to media when compared to the horizontal tablet orientation used in other studies 205 
(Abdelbary et al., 2005) (Dor and Fix, 2000) (Szakonyi and Zelkó, 2013) so as to more accurately 206 
represent the orientation of a tablet during use in a NSDS. Upon probe lowering, the tablet was 207 
immersed into 31 mL of media pre-heated to 37 ˚C using a hot plate (Gallenkamp, UK) in a 50 mL 208 
beaker. Immediately before experiments commenced, the beaker was moved to the texture 209 
analyser held at laboratory temperature, resulting in a media temperature always above 32˚C 210 
throughout the experiments.  This temperature range includes the range of temperature of artificial 211 
saliva mimicked in a previous texture analysis study (Abdelbary et al., 2005) and is relevant to the 212 
physiological temperature range of human milk in the NSDS. Media volume was chosen to ensure 213 
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complete tablet immersion in the beaker.  The platform contained concentric holes to minimize 214 
accumulation of disintegrated tablet material during testing and therefore more closely mimic the 215 
removal of disintegrated tablet that would occur in vivo or during delivery using the NSDS.  The hole 216 
diameter and spacing was chosen based on ease of manufacture. The centre of the platform 217 
remained non-perforated to prevent the tablet from being pressed through the platform by the 218 
probe during testing. A diagram of the apparatus is shown in Figure 2.  219 
Statistical analysis of the results was performed using GraphPad Prism (La Jolla, California, 220 
USA). 221 
3          Results and discussion 222 
3.1          Disintegration characterisation analysis method 223 
Two sets of data over time were collected during the experiments including the texture 224 
analyser probe’s vertical movement and the applied load by the probe.  These data profiles were 225 
compared against each other in post-experimental analysis.  226 
Three regions of the probe distance-time profile have been previously defined in the 227 
literature, termed the initial region (I), the ascending region (A), and the plateau region (P) as 228 
designated in Figure 3 (Abdelbary et al., 2005) (el-Arini and Clas, 2002). Previous studies have shown 229 
one ascending and one plateau region per tablet tested. In these previous studies, the critical point 230 
between the ascending and plateau region was defined as the termination of disintegration and 231 
used to calculate the onset of disintegration. This was based on extrapolation from the slope of the 232 
ascending region (Dor and Fix, 2000). At that critical time point, the probe plateaued because it 233 
could lower no further due to resistance from the platform.    234 
Probe load was maintained over all time apart from when the load measured decreased 235 
momentarily when the tablet integrity was compromised. These local load minima were due to 236 
inherent lags in the feedback response of the system to changes in the tablet structure as 237 
disintegration occurred. The load then returned to the set value (as the probe moved further down 238 
into the beaker). This was due to resistance from the remaining portion of tablet being detected in 239 
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the load feedback loop used by the texture analysis software.  When the load applied by the probe 240 
was superimposed over the position data over time it became evident that load minima occur during 241 
time frames of increased probe movement rate.  242 
As with the USP disintegration experimental method, it was hypothesised that tablet 243 
disintegration commenced from the moment of tablet contact with the media.  Specifically for the 244 
described method, tablet disintegration was considered to likely be occurring during the initial 245 
region (I) due to mechanisms such as dissolution and material loss following tablet hydration.  The 246 
ascending region, labelled A in Figure 3, was then assumed to occur due to substantial tablet 247 
fracture. This assumption was supported by load data, which indicated that there was a loss in tablet 248 
integrity to resist the probe in this region. This drop in load would be expected from a sudden 249 
change in tablet morphology such as tablet fracturing. 250 
In some cases there were multiple ascending and plateau regions, as shown in Figure 4. The 251 
detected local load minima in the ascending regions were hypothesised to indicate partial fracturing 252 
of the tablet. This was hypothesised because maintenance of constant load would be expected to be 253 
compromised due to sudden changes in the tablet owing to cracking. Following partial tablet 254 
cracking the probe then regained the specified load against the remaining tablet core, causing a 255 
plateau region. This observation suggests that partial disintegration of tablets and therefore tablet 256 
structure can be quantifiably characterised using this previously unstudied novel method.  257 
Since a disintegrated tablet is defined according to the USP 37 (U.S. Pharmacopeial 258 
Convention, 2014a) by a lack of palpable core, tablet disintegration could therefore be defined as 259 
complete at the time point corresponding to the local load minima within the final ascending region 260 
(A). This is the time point at which the last remaining remnant of tablet core has been compromised.   261 
The final plateau then corresponded to the probe pressing down on remaining disintegrated 262 
tablet and the platform. Total disintegration time was calculated by summing the time from the 263 
initiation of the initial region to the disintegration end-point with the time over which the tablet was 264 
lowered into the media. The tablet lowering time, beginning with tablet to media contact, was 265 
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calculated using the height of the media above the platform and the speed of the probe as the tablet 266 
lowered. In this study, the lowering time was 2.6s. This value could be changed through 267 
manipulation of opaque media volume, beaker size, or platform height in future studies to study the 268 
impact on tablet disintegration.  To our knowledge, this method is the first to use both position and 269 
load data in this way to identify absolute end points for disintegration. 270 
3.2         Results of texture analysis disintegration characterisation using various media 271 
Probe position data resulting from the texture analysis study of the SRB tablets and Flashtab 272 
placebo tablets in water, bovine milk, and human milk differ as shown in Figure 5. The tablet 273 
disintegration times, as identified using the described load data method, for which white markers 274 
are shown in Figure 5, are listed in Table 2.  275 
During experimentation, it was expected that after the first observed ascending region, 276 
tablet disintegration would be complete, but further data analysis and longer experimental data 277 
collection demonstrated that the assumed palpable core was still present in many cases afterwards. 278 
This could be discerned by observing the total change in probe distance, which should be close to 279 
but not equal to the diameter of the tablet. The probe was not expected to move the entire tablet 280 
diameter distance because broken up tablet material remains at the end of testing preventing probe 281 
contact with the platform. It should be noted that this strategy of observing total probe movement 282 
can be used in order to assess completion of testing in future studies. Data sets for which complete 283 
disintegration did not occur were not analysed in this study, leading to varying sample sizes.  284 
One Ethypharm Flashtab placebo tablet disintegrating in bovine milk as well as one in human 285 
milk stand out as having different position-time profiles than the others, as shown in Figure 5. These 286 
tablets are believed to have undergone disintegration in a different way than in the other tablets, 287 
potentially due to inherent internal or structural weaknesses leading to more large fractures, as 288 
suggested by the multiple ascending and plateau regions. These differences are clear using the 289 
texture analysis data, and provide additional understanding of disintegration behaviour to what 290 
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potentially would be observed using USP testing. This is hypothesised because the behaviour is 291 
identified before complete disintegration, the parameter tested in the USP method.  292 
Considering that all tablets disintegrated within 6 min using the texture analyser, this 293 
method has demonstrated itself to be a comparable method to assess tablet disintegration 294 
behaviour to USP testing in terms of time-burden. Since each tablet must be tested individually 295 
though, this method takes more time than the USP method, in which six tablets are typically tested 296 
in parallel (U.S. Pharmacopeial Convention, 2014a).  297 
In general, the SRB tablets disintegrated in a longer time frame than the Flashtab placebo 298 
tablets, and showed variability in repeat testing for various media types. This is likely due to 299 
compositional, geometry, size, surface area, and manufacturing method formulation differences 300 
between the tablets resulting in varying pore structures and tablet disintegration characteristics. 301 
Future testing would be necessary to determine the main cause of variability. 302 
Based on one-way ANOVA, the disintegration time of the SRB tablets in the different media 303 
were found to be significantly different (P<0.0001), as were those for the Flashtab Placebo tablets 304 
(P<0.0001). Based on the Tukey multiple comparisons test, the SRB tablets and Flashtab Placebo 305 
tablets disintegration times were each statistically different in each milk compared to water, 306 
disintegrating faster in water (adjusted P value <0.0001 for both tablets).  Based on this test, the 307 
disintegration time of the SRB tablets in each milk media were significantly different from one 308 
another also (adjusted P value <0.0001), disintegrating faster in human milk than bovine milk. The 309 
Tukey multiple comparisons test indicated that the Flashtab Placebo tablets had no significant 310 
difference between the disintegration times for the two milk media (adjusted P value = 0.1685).  For 311 
each condition, the standard deviation of the average disintegration time was relatively small, 312 
indicating robustness of the method for reproducibly determining tablet disintegration times.  313 
Differences in media viscosity, surface tension, and composition, as well as contact angle to 314 
the tablet are likely dominating factors in influencing tablet disintegration due to their influence on 315 
liquid penetration rates into the tablet (Abrahamsson et al., 2004) (Anwar et al., 2005).  Tablets have 316 
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been shown to disintegrate slower in bovine milk than in water due to higher viscosity and lower 317 
surface tension that cause a decrease in liquid penetration rate, preventing wetting (Anwar et al, 318 
2005). Whereas the viscosity of water and bovine milk is different (reported as 0.6915 mPa·s and 1.3 319 
mPa·s, respectively) (Anwar et al, 2005), that of bovine and human milk (averaging 1.35 mPa·s - 1.5 320 
mPa·s) is less so (McDaniel et al., 1989). This suggests viscosity may not be the main cause for the 321 
differing disintegration times of the SRB tablets between each milk media. Compositional differences 322 
between the media may have led to differing tablet disintegration times. Protein presence in media 323 
has been shown to have a large effect on tablet disintegration time due to protein and carbohydrate 324 
film formation on the tablets preventing liquid penetration (Abrahamsson et al, 2004).  Protein 325 
concentration in the human and bovine milk differed (being 1.8 wt% and 3.3 w/v%, respectively), 326 
which may have caused differing film formation on the SRB tablets, resulting in differing tablet 327 
disintegration times. It is noted that fat content of the media, being 3.4 wt% for the human milk and 328 
4 w/v% for bovine milk, were similar, and so are unlikely to be a main cause of tablet disintegration 329 
time variability.  330 
Future studies assessing tablet disintegration in various other opaque media using texture 331 
analysis could be performed, such as fruit juices or other solutions to which tablets used as 332 
medicines, vitamins, minerals, or flavour enhancers are added.  Studies which assess the impact of 333 
manufacturing processes on tablet solid fraction and the resulting tablet disintegration time 334 
uniformity could also be completed. These studies could be valuable in setting manufacturing 335 
specifications such as tableting compression values. Disintegration testing in opaque media could 336 
have wider implications outside of pharmaceutical commercialisation as well, such as for 337 
characterisation of tablets added to opaque emulsions, solutions, or mixtures in commercial 338 
processes.  Additionally, texture analysis testing of tablets in mixing liquids could be performed to 339 
understand how media movement impacts tablet disintegration. These tests may serve to mimic the 340 
solution movement which may be present during various tablet disintegration processes, such as the 341 
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stirring of a media to which a tablet has been added, or the churning of the stomach into which a 342 
tablet enters.   343 
4 Conclusion 344 
Assessment of tablet disintegration properties has been shown possible in opaque fluids 345 
using texture analysis disintegration testing. This technique allows for quantitative determination of 346 
disintegration end point times independent of observation. This is especially beneficial for 347 
characterising disintegration of rapidly disintegrating and dispersible tablets, for which 348 
characterisation can be challenging due to the fast speed at which the tablets disintegrate 349 
complicating visual discernment of disintegration completion end point times in the USP method. 350 
Additionally, this study demonstrates a novel analytical method of assessing data collected in the 351 
constant load texture analysis method. In this method, load data is shown to be useful for 352 
characterisation of tablet fracturing behaviour prior to complete tablet disintegration, a phenomena 353 
which is not quantitatively measurable using USP methods.  By identifying time points corresponding 354 
to local probe load minima during the constant load texture analysis technique, corresponding 355 
hypothesised instances of tablet fracture are identified. Final tablet disintegration is then defined as 356 
complete following the time point corresponding to the final tablet fracture. 357 
The results of the study have shown texture analysis could be useful in further characterising 358 
the disintegration behaviour in human milk of potential tablet formulations for use in a nipple shield 359 
delivery system, a novel method for delivery of life-saving medications or nutrients to breastfeeding 360 
infants.  Various supplemental or therapeutic tablet formulations could be studied in human milk 361 
with compositions ranging in fat and protein content to robustly characterise potential formulations 362 
in the range of conditions which may be present resulting from breastfeeding. Additionally, this 363 
texture analysis method could allow for characterisation of tablet formulations in opaque media for 364 
other commercial development purposes. Generally, this method could be used to assess the 365 
likelihood of internal tablet fracture resulting from various tablet manufacturing methods. This 366 
information could be used to define tablet solid fraction specifications and corresponding tablet 367 
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manufacturing process specifications. Further method development studies could also be performed 368 
to determine how load induced by the probe during testing may impact tablet disintegration 369 
uniformity for tablets in the presented vertical orientation, as has been performed with tablets 370 
placed horizontally in other texture analysis studies (Dor and Fix, 2000). 371 
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Figure Captions 447 
Figure 1. An illustration of the Nipple Shield Delivery System (NSDS) during use delivering an active 448 
pharmaceutical ingredient (API) into an infant during breastfeeding – provided courtesy of 449 
justmilk.org. 450 
Figure 2. Illustrations of Experimental Setup. (a) Demonstration of the attachment of the tablet in a 451 
vertical orientation to the texture analyser probe. (b) Platform diagram (2) 452 
Figure 3. Texture analyser probe data from the point of tablet contact with the platform for a single 453 
trial of a SRB tablet disintegrating in water. The initial, ascending and plateau regions are labeled I, A, 454 
and P, respectively, as based on the labeling conventions of Abdelbary et al.. (a) Position data. (b) 455 
Position data overlaid with load data. 456 
Figure 4. Texture analyser probe data from the point of tablet contact with the platform for a single 457 
trial of a Sybedia Flashtab placebo tablet disintegrating in human milk. The initial, ascending and 458 
plateau regions are labeled I, A, and P, respectively, as based on the labeling conventions of 459 
Abdelbary et al.. (a) Position data. (b) Position data overlaid with load data. 460 
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Figure 5. Probe position data during texture analysis disintegration testing from the point of tablet to 461 
platform contact. (a) SRB tablets and (b) Sybedia Flashtab placebo tablets in (i) Water, (ii) Bovine 462 
Milk, and (iii) Human Milk. Calculated disintegration end points are shown as white circles (ᴏ). 463 
 Table 1 
Laboratory-manufactured tablet composition. 
 
 
 
Chemical Role w/w Grade Manufacturer 
Sulforhodamine B (Sigma) Model compound   2.6 75% Purity Sigma-Aldrich, Dorset, UK 
Lactose (SuperTab 14SD) Filler 91.4 Ph. Eur DFE Pharma, Goch, Germany 
Sodium starch glycolate (Explotab CLV) Superdisintegrant   3.0 Typ (A) Ph. Eur Mendell GmbH, Volklingen, Germany 
Croscarmellose sodium (Ac-Di-Sol) Superdisintegrant   2.0 Ph. Eur FMC Biopolymer, Girvan, UK 
Magnesium stearate Lubricant   1.0 Technical Grade Sigma-Aldrich, Dorset, UK 
Table(1)
Table 2 
Physical characteristics of orally disintegrating tablets using United States Pharmacopoeia methods.  
Tablet  SRB tablets Sybedia Flashtab placebo tablets  
Manufacturer Laboratory-manufactured Ethypharm 
 Average + standard deviation n
 
Average + standard deviation n 
Height (mm) 4.52 + 0.08 10 2.09 + 0.06 10 
Width (mm) 5.98 + 0.02 10 3.69 + 0.02 10 
Diameter (mm) 8.088 + 0.004 10 8.147 + 0.006 10 
Weight (mg) 330 + 1 10 150 + 2 10 
Hardness (N) 39 + 3 10 23 + 1 10 
Tensile Strength (MPa) 0.53 + 0.04 10 0.50 + 0.03 10 
Disintegration time (s) 30 + 2   6 23 + 2   6 
n: number of samples; tensile strength was calculated assuming right cylindrical tablet geometry (U.S. Pharmacopeial Convention, 2014b)  
 
 
 
Table(2) (Revised)
Table 3  
Average disintegration times for each tablet in various media using texture analysis disintegration 
testing. 
n: number of samples 
 
 
 SRB tablets Sybedia Flashtab placebo tablets 
 Average disintegration time (s) + standard deviation n
 
Average disintegration time (s) + standard  deviation n 
Water 82 + 7 8 23 + 4 5 
Bovine milk 336 + 2 3 88 + 7 5 
Human milk 122 + 9 4 81 + 4 5 
Table(3)
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